New app and urine test aim to boost HIV med adherence in men who use stimulants

NCT ID NCT07125235

Recruiting now Disease control Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a program called reSTART for men living with HIV who also use stimulants. It combines a smartphone app, a urine test to check medication levels, and motivational messages to help them remember to take their HIV drugs. The goal is to see if this approach can lower their viral load and reduce stimulant use. About 270 men are being recruited for this trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mobile health app and urine tenofovir self-test
What this could lead to: If successful, this could provide a practical tool to help men with HIV and stimulant use stay on their medication and achieve viral suppression.
What could go wrong: This is a relatively small, early-stage trial (270 participants) focused on a specific group, so results may not apply broadly. The intervention relies on self-monitoring, which may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ART ADHERENCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ART ADHERENCE BEHAVIORAL INTERVENTION VIRAL SUPPRESSION OF HIV INFECTION

Contacts and locations

Locations

University of California, San Francisco
RECRUITING

San Francisco, California, 94110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.